{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:13:54Z","timestamp":1792088034502,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"national cancer institute","award":["UM1CA186690"],"award-info":[{"award-number":["UM1CA186690"]}]},{"name":"national cancer institute","award":["P30CA047904"],"award-info":[{"award-number":["P30CA047904"]}]},{"name":"national cancer institute","award":["P30CA047904"],"award-info":[{"award-number":["P30CA047904"]}]},{"name":"national cancer institute","award":["U24CA247643"],"award-info":[{"award-number":["U24CA247643"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00280-024-04720-1","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T04:43:16Z","timestamp":1734151396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)"],"prefix":"10.1007","volume":"95","author":[{"given":"Sarah E.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Behr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine L.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haider","family":"Mahdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Fabian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Gallion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Girda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Courtney-Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander B.","family":"Olawaiye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie M.","family":"Randall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Christner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushil","family":"Beriwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise C.","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Kunos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Percy","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8978-9401","authenticated-orcid":false,"given":"Jan H.","family":"Beumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,14]]},"reference":[{"key":"4720_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA: a cancer journal for clinicians 70. 17\u201330. https:\/\/doi.org\/10.3322\/caac.21590","DOI":"10.3322\/caac.21590"},{"issue":"1","key":"4720_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00404-010-1385-5","volume":"283","author":"N Wang","year":"2011","unstructured":"Wang N, Guan QL, Wang K, Zhou X, Gao C, Yang HT, Ni TG (2011) Radiochemotherapy versus radiotherapy in locally advanced cervical cancer: a meta-analysis. Arch Gynecol Obstet 283(1):103\u2013108. https:\/\/doi.org\/10.1007\/s00404-010-1385-5","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"4720_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/AOG.0000000000003311","volume":"134","author":"JD Wright","year":"2019","unstructured":"Wright JD, Matsuo K, Huang Y, Tergas AI, Hou JY, Khoury-Collado F, St Clair CM, Ananth CV, Neugut AI, Hershman DL (2019) Prognostic performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging guidelines. Obstet Gynecol 134(1):49\u201357. https:\/\/doi.org\/10.1097\/AOG.0000000000003311","journal-title":"Obstet Gynecol"},{"issue":"9","key":"4720_CR4","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1097\/IGC.0b013e318270577f","volume":"22","author":"CA Kunos","year":"2012","unstructured":"Kunos CA, Radivoyevitch T, Kresak A, Dawson D, Jacobberger J, Yang B, Abdul-Karim FW (2012) Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers. Int J Gynecol cancer: Official J Int Gynecol Cancer Soc 22(9):1463\u20131469. https:\/\/doi.org\/10.1097\/IGC.0b013e318270577f","journal-title":"Int J Gynecol cancer: Official J Int Gynecol Cancer Soc"},{"issue":"1","key":"4720_CR5","first-page":"55","volume":"8","author":"CA Kunos","year":"2012","unstructured":"Kunos CA (2012) Therapeutic mechanisms of treatment in cervical and vaginal Cancer. Oncol Hematol Rev 8(1):55\u201360","journal-title":"Oncol Hematol Rev"},{"issue":"6","key":"4720_CR6","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1667\/RR1858.1","volume":"172","author":"CA Kunos","year":"2009","unstructured":"Kunos CA, Chiu SM, Pink J, Kinsella TJ (2009) Modulating radiation resistance by inhibiting ribonucleotide reductase in cancers with virally or mutationally silenced p53 protein. Radiat Res 172(6):666\u2013676. https:\/\/doi.org\/10.1667\/RR1858.1","journal-title":"Radiat Res"},{"issue":"5","key":"4720_CR7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1667\/RR2273.1","volume":"174","author":"CA Kunos","year":"2010","unstructured":"Kunos CA, Radivoyevitch T, Pink J, Chiu SM, Stefan T, Jacobberger J, Kinsella TJ (2010) Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat Res 174(5):574\u2013581. https:\/\/doi.org\/10.1667\/RR2273.1","journal-title":"Radiat Res"},{"key":"4720_CR8","doi-asserted-by":"publisher","unstructured":"Hreshchyshyn MM (1975) Gynecologic Oncology Group reports I and II. Gynecologic oncology 3. 3251\u2013257. https:\/\/doi.org\/10.1016\/s0090-8258(75)80010-2","DOI":"10.1016\/s0090-8258(75)80010-2"},{"issue":"9","key":"4720_CR9","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1007\/s00216-018-0889-x","volume":"410","author":"K Pelivan","year":"2018","unstructured":"Pelivan K, Frensemeier LM, Karst U, Koellensperger G, Heffeter P, Keppler BK, Kowol CR (2018) Comparison of metabolic pathways of different alpha-N-heterocyclic thiosemicarbazones. Anal Bioanal Chem 410(9):2343\u20132361. https:\/\/doi.org\/10.1007\/s00216-018-0889-x","journal-title":"Anal Bioanal Chem"},{"issue":"5","key":"4720_CR10","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00280-020-04154-5","volume":"86","author":"A Joshi","year":"2020","unstructured":"Joshi A, Kiesel BF, Chaphekar N, Jones R, Guo J, Kunos CA, Taylor S, Chu E, Venkataramanan R, Beumer JH (2020) In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine. Cancer Chemother Pharmacol 86(5):633\u2013640. https:\/\/doi.org\/10.1007\/s00280-020-04154-5","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4720_CR11","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1158\/1078-0432.CCR-09-2469","volume":"16","author":"CA Kunos","year":"2010","unstructured":"Kunos CA, Waggoner S, von Gruenigen V, Eldermire E, Pink J, Dowlati A, Kinsella TJ (2010) Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin Cancer Res 16(4):1298\u20131306. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2469","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4720_CR12","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ygyno.2013.04.019","volume":"130","author":"CA Kunos","year":"2013","unstructured":"Kunos CA, Radivoyevitch T, Waggoner S, Debernardo R, Zanotti K, Resnick K, Fusco N, Adams R, Redline R, Faulhaber P, Dowlati A (2013) Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers. Gynecol Oncol 130(1):75\u201380. https:\/\/doi.org\/10.1016\/j.ygyno.2013.04.019","journal-title":"Gynecol Oncol"},{"key":"4720_CR13","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.3389\/fonc.2019.01067","volume":"9","author":"CA Kunos","year":"2019","unstructured":"Kunos CA, Andrews SJ, Moore KN, Chon HS, Ivy SP (2019) Randomized Phase II Trial of Triapine-Cisplatin-Radiotherapy for locally advanced stage uterine cervix or vaginal cancers. Front Oncol 9:1067. https:\/\/doi.org\/10.3389\/fonc.2019.01067","journal-title":"Front Oncol"},{"issue":"16suppl","key":"4720_CR14","doi-asserted-by":"publisher","first-page":"5502","DOI":"10.1200\/JCO.2023.41.16_suppl.5502","volume":"41","author":"CA Leath","year":"2023","unstructured":"Leath CA, Deng W, Mell LK, Richardson DL, Walker JL, Holman LL, Lea JS, Amarnath SR, Santos-Reyes LJ, Arend RC, Mayadev J, Jegadeesh N, Disilvestro P, Chon HS, Ghamande SA, Quick AM, Chino JP, Mackay H, Aghajanian C, Monk BJ (2023) Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: results from NRG-GY006, a phase III randomized trial. JCO 41(16suppl):5502\u20135502. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.5502","journal-title":"JCO"},{"issue":"3","key":"4720_CR15","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s00280-011-1779-5","volume":"69","author":"J Chao","year":"2012","unstructured":"Chao J, Synold TW, Morgan RJ Jr., Kunos C, Longmate J, Lenz HJ, Lim D, Shibata S, Chung V, Stoller RG, Belani CP, Gandara DR, McNamara M, Gitlitz BJ, Lau DH, Ramalingam SS, Davies A, Espinoza-Delgado I, Newman EM, Yen Y (2012) A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer Chemother Pharmacol 69(3):835\u2013843. https:\/\/doi.org\/10.1007\/s00280-011-1779-5","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"4720_CR16","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1200\/JCO.2004.07.158","volume":"22","author":"S Wadler","year":"2004","unstructured":"Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, Sznol M (2004) Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncology: Official J Am Soc Clin Oncol 22(9):1553\u20131563. https:\/\/doi.org\/10.1200\/JCO.2004.07.158","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"3","key":"4720_CR17","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/ajh.20547","volume":"81","author":"LM Foltz","year":"2006","unstructured":"Foltz LM, Dalal BI, Wadsworth LD, Broady R, Chi K, Eisenhauer E, Kobayashi K, Kollmannsburger C (2006) Recognition and management of methemoglobinemia and hemolysis in a G6PD-deficient patient on experimental anticancer drug Triapine. Am J Hematol 81(3):210\u2013211. https:\/\/doi.org\/10.1002\/ajh.20547","journal-title":"Am J Hematol"},{"issue":"2","key":"4720_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.2217\/fon.11.147","volume":"8","author":"CA Kunos","year":"2012","unstructured":"Kunos CA, Radivoyevitch T, Ingalls ST, Hoppel CL (2012) Management of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone-induced methemoglobinemia. Future Oncol 8(2):145\u2013150. https:\/\/doi.org\/10.2217\/fon.11.147","journal-title":"Future Oncol"},{"key":"4720_CR19","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jpba.2017.08.036","volume":"146","author":"J Matsumoto","year":"2017","unstructured":"Matsumoto J, Kiesel BF, Parise RA, Guo J, Taylor S, Huang M, Eiseman JL, Ivy SP, Kunos C, Chu E, Beumer JH (2017) LC-MS\/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma. J Pharm Biomed Anal 146:154\u2013160. https:\/\/doi.org\/10.1016\/j.jpba.2017.08.036","journal-title":"J Pharm Biomed Anal"},{"issue":"19","key":"4720_CR20","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1001\/jama.298.19.2289","volume":"298","author":"JK Schwarz","year":"2007","unstructured":"Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW (2007) Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA: J Am Med Association 298(19):2289\u20132295. https:\/\/doi.org\/10.1001\/jama.298.19.2289","journal-title":"JAMA: J Am Med Association"},{"issue":"5","key":"4720_CR21","doi-asserted-by":"publisher","first-page":"e74","DOI":"10.3802\/jgo.2021.32.e74","volume":"32","author":"C Onal","year":"2021","unstructured":"Onal C, Guler OC, Reyhan M, Yapar AF (2021) Long-term outcomes of cervical cancer patients with complete metabolic response after definitive chemoradiotherapy. J Gynecol Oncol 32(5):e74. https:\/\/doi.org\/10.3802\/jgo.2021.32.e74","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"4720_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijrobp.2011.05.053","volume":"83","author":"JK Schwarz","year":"2012","unstructured":"Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW (2012) Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 83(1):185\u2013190. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.05.053","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"4720_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ygyno.2012.08.006","volume":"127","author":"S Beriwal","year":"2012","unstructured":"Beriwal S, Kannan N, Sukumvanich P, Richard SD, Kelley JL, Edwards RP, Olawaiye A, Krivak TC (2012) Complete metabolic response after definitive radiation therapy for cervical cancer: patterns and factors predicting for recurrence. Gynecol Oncol 127(2):303\u2013306. https:\/\/doi.org\/10.1016\/j.ygyno.2012.08.006","journal-title":"Gynecol Oncol"},{"issue":"5","key":"4720_CR24","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.ijrobp.2008.03.040","volume":"72","author":"JK Schwarz","year":"2008","unstructured":"Schwarz JK, Lin LL, Siegel BA, Miller TR, Grigsby PW (2008) 18-F-fluorodeoxyglucose-positron emission tomography evaluation of early metabolic response during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 72(5):1502\u20131507. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.03.040","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"11","key":"4720_CR25","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s40262-016-0400-9","volume":"55","author":"GD Anderson","year":"2016","unstructured":"Anderson GD, Chan LN (2016) Pharmacokinetic drug interactions with Tobacco, cannabinoids and Smoking Cessation products. Clin Pharmacokinet 55(11):1353\u20131368. https:\/\/doi.org\/10.1007\/s40262-016-0400-9","journal-title":"Clin Pharmacokinet"},{"issue":"4suppl","key":"4720_CR26","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1200\/JCO.2023.41.4_suppl.648","volume":"41","author":"A Chauhan","year":"2023","unstructured":"Chauhan A, Christner SM, Beumer JH, Kunos C, Khurana A, Khouli RE, Weiss H, Yan D, Soares HP, Halfdanarson TR, Li D, Carson WE, Evers MB, Ivy P, Kohn EC, Rubinstein L, Arnold SM, Kolesar J, Anthony LB, Konda B (2023) Pharmacokinetics and RP2D analysis from ETCTN 10388: a phase I trial of triapine and lutetium Lu-177 dotatate in well-differentiated somatostatin receptor\u2013positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). JCO 41(4suppl):648\u2013648. https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.648","journal-title":"JCO"},{"issue":"15","key":"4720_CR27","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","volume":"340","author":"PG Rose","year":"1999","unstructured":"Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340(15):1144\u20131153. https:\/\/doi.org\/10.1056\/NEJM199904153401502","journal-title":"N Engl J Med"},{"issue":"5","key":"4720_CR28","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.1097\/MJT.0000000000001277","volume":"28","author":"BK Wills","year":"2020","unstructured":"Wills BK, Cumpston KL, Downs JW, Rose SR (2020) Causative agents in clinically significant methemoglobinemia: a national poison Data System Study. Am J Ther 28(5):e548\u2013e551. https:\/\/doi.org\/10.1097\/MJT.0000000000001277","journal-title":"Am J Ther"},{"issue":"12","key":"4720_CR29","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/ajh.26340","volume":"96","author":"A Iolascon","year":"2021","unstructured":"Iolascon A, Bianchi P, Andolfo I, Russo R, Barcellini W, Fermo E, Toldi G, Ghirardello S, Rees D, Van Wijk R, Kattamis A, Gallagher PG, Roy N, Taher A, Mohty R, Kulozik A, De Franceschi L, Gambale A, De Montalembert M, Forni GL, Harteveld CL, Prchal J (2021) Recommendations for diagnosis and treatment of methemoglobinemia. Am J Hematol 96(12):1666\u20131678 cell SWGor, iron of EHA, EuroBloodNet. https:\/\/doi.org\/10.1002\/ajh.26340","journal-title":"Am J Hematol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04720-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-024-04720-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-024-04720-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T05:05:42Z","timestamp":1734152742000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-024-04720-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,14]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4720"],"URL":"https:\/\/doi.org\/10.1007\/s00280-024-04720-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,14]]},"assertion":[{"value":"25 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was an NCI, CTEP sponsored, multicenter trial performed at five NCI-designated cancer centers, approved by the respective institutional review boards and ethics committees, under the NCI CIRB as the IRB of record. All participants signed informed consent, priort to research procedures, with adherence to the ethical principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This trial was registered under ClinicalTrials.gov Identifier: NCT02595879.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no potential conflicts of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare no competing interests.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}